Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 7/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924877 | 0.91 | PIK3C3 (0.38) | TRPA1CYP17A1CYP21A2CYP11B1PRKD1 | |
| SCHEMBL6927297 | 0.90 | DRD2 (0.43) | DRD2DRD4DRD3HTR2AHTR1A | |
| SCHEMBL6927160 | 0.90 | DRD2 (0.43) | DRD2DRD4DRD3PRKD1HTR2A | |
| SCHEMBL6927463 | 0.89 | KDM4E (0.40) | PRKD1HTR2A | |
| SCHEMBL6922166 | 0.89 | PIK3C3 (0.40) | DRD2DRD4DRD3CYP17A1CYP21A2 | |
| SCHEMBL6923588 | 0.87 | PIK3C3 (0.40) | DRD2DRD4DRD3PRKD1 | |
| SCHEMBL6924961 | 0.87 | DRD4 (0.42) | TRPA1DRD2DRD4DRD3HTR2A | |
| SCHEMBL6925464 | 0.87 | DRD2 (0.44) | DRD2DRD4DRD3HTR2AHTR1A | |
| SCHEMBL7670455 | 0.85 | LRRK2 (0.44) | DRD2DRD4DRD3HTR2AHTR1A | |
| SCHEMBL6925249 | 0.85 | ITGB2 (0.49) | DRD2DRD4DRD3HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | TRPA1 2314/4885DRD2 1447/4885DRD4 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.